These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7681213)

  • 1. The role of cytokines in the therapy of renal cell carcinoma.
    Ebert T; Schmitz-Dräger BJ; Ackermann R
    Recent Results Cancer Res; 1993; 126():113-8. PubMed ID: 7681213
    [No Abstract]   [Full Text] [Related]  

  • 2. Renal cell carcinoma and interleukin-2: a review.
    Wagstaff J; Baars JW; Wolbink GJ; Hoekman K; Eerenberg-Belmer AJ; Hack CE
    Eur J Cancer; 1995; 31A(3):401-8. PubMed ID: 7540404
    [No Abstract]   [Full Text] [Related]  

  • 3. The management of renal cell carcinoma.
    Pittman K; Selby P
    Crit Rev Oncol Hematol; 1994 Jun; 16(3):181-200. PubMed ID: 7521169
    [No Abstract]   [Full Text] [Related]  

  • 4. Interferons and interleukins in metastatic renal cell carcinoma.
    Choudhury M; Efros M; Mittelman A
    Urology; 1993 Jan; 41(1 Suppl):67-72. PubMed ID: 7678365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current use of interferons, interleukin-2 and tumor necrosis factor in renal cell cancer.
    Wirth M
    Urol Int; 1991; 47(4):219-30. PubMed ID: 1723554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The value of interferons, interleukin-2 and tumor necrosis factor in the therapy of renal cell cancer].
    Wirth M
    Urologe A; 1991 Mar; 30(2):77-80. PubMed ID: 1711729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA; Benyunes MC; Bianco JA; Fefer A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract]   [Full Text] [Related]  

  • 8. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
    Hermann GG
    APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of interleukin-2 in the biotherapy of cancer.
    Parkinson DR
    Oncol Nurs Forum; 1989; 16(6 Suppl):16-20. PubMed ID: 2687810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-2: efficacy in renal cell carcinoma and overall safety profile.
    Louie A
    Cancer Invest; 1990; 8(2):315-6. PubMed ID: 2400958
    [No Abstract]   [Full Text] [Related]  

  • 11. Rapid exacerbation of scleroderma in a patient treated with interleukin 2 and lymphokine activated killer cells for renal cell carcinoma.
    Puett DW; Fuchs HA
    J Rheumatol; 1994 Apr; 21(4):752-3. PubMed ID: 8035405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-2 therapy proves durable in renal cell melanoma patients.
    Oncology (Williston Park); 1991 Sep; 5(9):71. PubMed ID: 1835879
    [No Abstract]   [Full Text] [Related]  

  • 13. Biological therapy for metastatic renal cell cancer.
    Lancet; 1991 Mar; 337(8740):522-3. PubMed ID: 1705643
    [No Abstract]   [Full Text] [Related]  

  • 14. In vivo activation of LAK cells during systemic IL-2 therapy.
    Lang P; Vitté-Mony I; Farace F; Stancou R; Triebel F; Escudier B; Hercend T; Bertoglio J
    Eur Cytokine Netw; 1990; 1(3):185-8. PubMed ID: 2129800
    [No Abstract]   [Full Text] [Related]  

  • 15. High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma.
    Parkinson DR; Sznol M
    Semin Oncol; 1995 Feb; 22(1):61-6. PubMed ID: 7855620
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.
    Gaynor ER; Weiss GR; Margolin KA; Aronson FR; Sznol M; Demchak P; Grima KM; Fisher RI; Boldt DH; Doroshow JH
    J Natl Cancer Inst; 1990 Sep; 82(17):1397-402. PubMed ID: 2388289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells.
    Kuebler JP; Whitehead RP; Ward DL; Hemstreet GP; Bradley EC
    J Urol; 1993 Sep; 150(3):814-20. PubMed ID: 8345590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of disseminated renal cell cancer with combinations of interleukin-2, lymphokine-activated killer cells, and alpha-interferon.
    Stoter G; Goey SH; Batchelor D; Eggermont AM; Lamers C; Gratama JW; Bolhuis RL
    Prog Clin Biol Res; 1992; 378():225-33. PubMed ID: 1301583
    [No Abstract]   [Full Text] [Related]  

  • 19. Biologic response modifiers in the therapy of metastatic renal cell carcinoma.
    Quesada JR
    Semin Oncol; 1988 Aug; 15(4):396-407. PubMed ID: 2457256
    [No Abstract]   [Full Text] [Related]  

  • 20. Medical treatment of advanced renal cell carcinoma: present options and future directions.
    Canobbio L; Miglietta L; Boccardo F
    Cancer Treat Rev; 1996 Mar; 22(2):85-104. PubMed ID: 8665566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.